ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval
Retrieved on:
Wednesday, November 1, 2023
Manufacturing, Finance, Pharmaceutical, General Health, Professional Services, Philanthropy, Hospitals, Genetics, Clinical Trials, Other Manufacturing, Foundation, Biotechnology, Science, Other Science, Research, Health, Child, ICH, AAV, Health care, Therapy, Rare, Rare disease, United Arab Emirates, Organic, UCL, CGT, Multimedia, Lentivirus, Great Ormond Street Hospital, Growth, GOSH, Cell, ZCR, MHRA, Association de médiation sociale v Union locale des syndicats CGT, Partnership, Zayed Center for Coordination and Follow-Up, Zayed bin Sultan Al Nahyan, GMP, Patient, MIA, Vaccine, Hospital
This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.
Key Points:
- This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.
- With ViroCell now able to leverage GOSH's state-of-the-art manufacturing facility, the Company is poised to relieve the strain on clinical research caused by the vector shortage and expand the supply of precisely engineered viral vectors for clinical trials.
- The MHRA is widely considered a gold-standard regulatory authority, with its rigorous requirement for facility inspection and licencing for advanced therapy manufacturing for clinical trials.
- Therefore, in addition to accelerating CGT clinical trials in the UK, this approval could also help accelerate the start of new clinical trials worldwide, as ViroCell ramps up the manufacturing of vectors for global export.